Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has entered into a licensing agreement with Statens Serum Institut (SSI) to further develop and commercialize anti-cancer vaccines using Evaxion’s proprietary PIONEER platform, which utilizes artificial intelligence for vaccine design. SSI, specializing in disease control and research, provides a proprietary liposomal adjuvant formulation for the partnership. The collaboration aims to advance personalized medicine in cancer treatment, supported by Innovations Fund Denmark.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
